Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects
- PMID: 1850964
- DOI: 10.1164/ajrccm/143.5_Pt_1.1025
Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects
Abstract
Urinary leukotriene E4 (LTE4) concentrations have been measured in six asthmatic patients with aspirin sensitivity and in five asthmatic subjects tolerant of aspirin, before and after provocation with aspirin or placebo. Aspirin-sensitive subjects showed an average 21% fall in FEV1 after aspirin challenge whereas control individuals had a 2% fall in FEV1 after ingestion of 100 mg aspirin. The resting urinary LTE4 concentrations in asthmatic subjects sensitive to aspirin were 243 pg/mg creatinine (range 50 to 1,041), and these were on average sixfold greater than those in control asthmatic subjects. Further, there was a mean fourfold increase in urinary LTE4 levels at 3 to 6 h after aspirin, but not placebo, challenge in aspirin-sensitive asthmatic subjects that was not seen in the control asthmatic individuals. Leukotriene release may play a central role in the mechanisms of asthmatic attacks produced by aspirin ingestion.
Similar articles
-
Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects.Am Rev Respir Dis. 1992 Dec;146(6):1531-4. doi: 10.1164/ajrccm/146.6.1531. Am Rev Respir Dis. 1992. PMID: 1333741 Clinical Trial.
-
Urinary leukotriene E4 in bronchial asthma.Eur Respir J. 1992 Jun;5(6):693-9. Eur Respir J. 1992. PMID: 1321055
-
Urinary leukotriene E4 levels after allergen and exercise challenge in bronchial asthma.Am Rev Respir Dis. 1991 Dec;144(6):1411-3. doi: 10.1164/ajrccm/144.6.1411. Am Rev Respir Dis. 1991. PMID: 1660231
-
Sulphidopeptide leukotrienes in asthma.Adv Prostaglandin Thromboxane Leukot Res. 1991;21A:415-9. Adv Prostaglandin Thromboxane Leukot Res. 1991. PMID: 1847780 Review.
-
Inhalation challenge with sulfidopeptide leukotrienes in human subjects.Chest. 1986 Mar;89(3):414-9. doi: 10.1378/chest.89.3.414. Chest. 1986. PMID: 3512190 Review.
Cited by
-
Mast Cells in Aspirin-Exacerbated Respiratory Disease.Curr Allergy Asthma Rep. 2024 Feb;24(2):73-80. doi: 10.1007/s11882-024-01125-1. Epub 2024 Jan 13. Curr Allergy Asthma Rep. 2024. PMID: 38217825 Review.
-
The role of oxylipins in NSAID-exacerbated respiratory disease (N-ERD).Adv Pharmacol. 2023;97:423-444. doi: 10.1016/bs.apha.2022.12.002. Epub 2023 Jan 10. Adv Pharmacol. 2023. PMID: 37236766 Free PMC article.
-
Aspirin-exacerbated respiratory disease: Updates in the era of biologics.Ann Allergy Asthma Immunol. 2023 Sep;131(3):317-324. doi: 10.1016/j.anai.2023.05.016. Epub 2023 May 22. Ann Allergy Asthma Immunol. 2023. PMID: 37225000 Review.
-
Urinary Leukotriene E4 as a Biomarker in NSAID-Exacerbated Respiratory Disease (N-ERD): a Systematic Review and Meta-analysis.Curr Allergy Asthma Rep. 2022 Dec;22(12):209-229. doi: 10.1007/s11882-022-01049-8. Epub 2022 Nov 14. Curr Allergy Asthma Rep. 2022. PMID: 36374376 Free PMC article. Review.
-
Updates on immune mechanisms in aspirin-exacerbated respiratory disease.J Allergy Clin Immunol. 2023 Feb;151(2):301-309. doi: 10.1016/j.jaci.2022.08.021. Epub 2022 Sep 30. J Allergy Clin Immunol. 2023. PMID: 36184313 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
